Skip to content.

Aptose Biosciences announces license agreement with CrystalGenomics for CG-806

Date Closed

June 14, 2018

Lead Office

Québec City


125.00 Million USD

On June 14, 2018, Aptose Biosciences Inc. announced that it has entered into a license agreement with CrystalGenomics, Inc. for China rights to CG-806. Aptose had exercised its option to obtain the exclusive license from CrystalGenomics to develop and commercialize CG-806 worldwide outside of China and Korea on May 7, 2018. Per this new agreement,  the rights to develop and commercialize CG-806 are now extended to China (including People’s Republic of China, Hong Kong and Macau), and exclude Korea. Total deal value for the China territory, including the upfront payment, is up to US$125 million.

CG-806 is a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B-cell malignancies and other hematologic malignancies. In preclinical tests, CG-806 has demonstrated superior potency and a robust safety profile. Aptose expects to submit an Investigational New Drug application in late 2018 and initiate clinical trials immediately thereafter.

Aptose is a biopharmaceutical company focused on the discovery, research and development of anti-cancer therapies. 

McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Soulière.